Evidence map›Paper›PMID 37434984›Full record

ArticleFrontiers in oncology2023

Biallelic disruption of DDX41 activity is associated with distinct genomic and immunophenotypic hallmarks in acute leukemia.

Anne Tierens, Elizabeth Kagotho, Satoru Shinriki, Andrew Seto, Adam C Smith, Melanie Care, Dawn Maze, Hassan Sibai, Karen W Yee, Andre C Schuh and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
2.0field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. DDX41: exploring the roles of a versatile helicase.Biochemical Society transactions · 2024
    Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 3 countries.

Anne TierensDepartment of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada.
Elizabeth KagothoDepartment of Pathology and Laboratory Medicine, Aga Khan University Hospital, Nairobi, Kenya.
Satoru ShinrikiDepartment of Molecular Laboratory Medicine, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.
Andrew SetoDivision of Clinical Laboratory Genetics, Laboratory Medicine Program, University Health Network, Toronto, ON, Canada.
Adam C SmithDepartment of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada.
Melanie CareDivision of Clinical Laboratory Genetics, Laboratory Medicine Program, University Health Network, Toronto, ON, Canada.
Dawn MazeDepartment of Medicine Medical Oncology and Hematology, University of Toronto, Princess Margaret Cancer Centre, Toronto, ON, Canada.
Hassan SibaiDepartment of Medicine Medical Oncology and Hematology, University of Toronto, Princess Margaret Cancer Centre, Toronto, ON, Canada.
Karen W YeeDepartment of Medicine Medical Oncology and Hematology, University of Toronto, Princess Margaret Cancer Centre, Toronto, ON, Canada.
Andre C SchuhDepartment of Medicine Medical Oncology and Hematology, University of Toronto, Princess Margaret Cancer Centre, Toronto, ON, Canada.
Dennis Dong Hwan KimDepartment of Medicine Medical Oncology and Hematology, University of Toronto, Princess Margaret Cancer Centre, Toronto, ON, Canada.
Vikas GuptaDepartment of Medicine Medical Oncology and Hematology, University of Toronto, Princess Margaret Cancer Centre, Toronto, ON, Canada.
Mark D MindenDepartment of Medicine Medical Oncology and Hematology, University of Toronto, Princess Margaret Cancer Centre, Toronto, ON, Canada.
Hirotaka MatsuiDepartment of Molecular Laboratory Medicine, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.
José-Mario Capo-ChichiDepartment of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada.
Princess Margaret Cancer Centre · CAUniversity of Toronto · CAUniversity Health Network · CAKumamoto University · JPAga Khan University Hospital Nairobi · KE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Inherited Methods: Here, we studied the genetic profile, bone marrow morphology and immunophenotype of 51 patients with DDX41 mutations. We further assessed the functional impact of ten previously uncharacterized Results: Our results demonstrate that MDS/AML cases harboring two Discussion: Here, we expand on previous clinicopathologic findings on

Indexed as

acute leukemiabiallelicclinical pathologyDDX41 mutationsmyelodysplastic syndrome

Identifiers

PMID37434984
PMCPMC10331015
OpenAlexW4382135772

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.